RetinaCME
LECTURECME

Neovascular Age-related Macular Degeneration: Emerging Therapies With an EYE On Treatment Frequency

Author(s)/Faculty: Arshad M. Khanani, MD, MA; Diana V. Do, MD; Michael A. Singer, MD
Release Date: 8/28/2019Expiration Date: 8/27/2020
Credit Type: CMENumber of Credits: 1.25
Content Type: LectureProvider:
The treatment of neovascular age-related macular degeneration (nAMD) has been revolutionized through the introduction of intravitreal anti–vascular endothelial growth factor (anti-VEGF) therapy into management protocols. Maintenance of initial visual acuity gains requires continued intravitreal injections, leading to a treatment burden for the patient. Evaluation and modification of treatment protocols, along with new delivery systems and novel anti-VEGF therapies, have the potential to provide long-term visual acuity gains, while reducing treatment burden. In this recorded symposium, experts in the field discuss the current burden of treatment, evaluate new dosing and administration schedules, as well as review the safety and efficacy of therapies in late-stage development that have the potential to reduce treatment frequency in the management of nAMD.